


WHAT IS CLAIMED

1. A compound of Formula I



- 5 or a pharmaceutically acceptable salt thereof,
wherein

R^1 is $-\text{CH}_2\text{N}(\text{R}^2)_2$, $-\text{CH}_2\text{NR}^2\text{COR}^3$, $-\text{CH}_2\text{NR}^2\text{COOR}^3$, $-\text{CH}_2\text{NR}^2\text{CON}(\text{R}^2)_2$, $-\text{CH}_2\text{NR}^2\text{CONR}^2\text{N}(\text{R}^2)_2$, $-\text{CH}_2\text{NR}^2\text{SO}_2\text{R}^3$, $-\text{CON}(\text{R}^2)_2$, $-\text{C}=\text{NOR}^3$, $-\text{CH}_2\text{OR}^4$, $-\text{CH}_2\text{NR}^2\text{R}^4$, $-\text{CH}_2\text{R}^6$
10 or $-\text{CH}_2\text{OC}(\text{O})\text{N}(\text{R}^2)_2$.

each occurrence of R^2 is independently selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₃-C₆ cycloalkyl, wherein said C₁-C₆ alkyl, said C₂-C₆ alkenyl, and said C₃-C₆ cycloalkyl can be optionally substituted with up to four substituents, which are independently
15 selected from the group consisting of halogen, $-\text{OCH}_3$, $-\text{OH}$, $-\text{NH}_2$, $-\text{NHCH}_3$, and $-\text{N}(\text{CH}_3)_2$;

R^3 is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, a 4- or 5-membered heterocycloalkyl or C₃-C₆ cycloalkyl, wherein said C₁-C₆ alkyl, said C₂-C₆ alkenyl, said 4- or 5-membered heterocycloalkyl and said C₃-C₆ cycloalkyl can be optionally substituted with up to four substituents, which are
20 independently selected from the group consisting of halogen, C₁-C₆ alkyl, haloC₁-C₆ alkyl, CN, $-\text{OCH}_3$, $-\text{OH}$, $-\text{NH}_2$, $-\text{NHCH}_3$, and $-\text{N}(\text{CH}_3)_2$;

R^4 is H or a 5- or 6- membered heterocycle, which is optionally substituted with R^5 ;

25 R^5 is selected from the group consisting of H, halogen, C₁-C₆ alkyl, C₃-C₆ alkenyl, and C₃-C₆ cycloalkyl, wherein said C₁-C₆ alkyl, said C₃-C₆ alkenyl, and said C₃-C₆ cycloalkyl can be optionally substituted with up to four substituents, which are independently selected from the group consisting of halogen, $-\text{OCH}_3$, $-\text{OH}$, $-\text{NH}_2$, $-\text{NHCH}_3$, and $-\text{N}(\text{CH}_3)_2$;

R^6 is H, C₁-C₆ alkyl, or a 5-membered heterocycle, wherein said 5-membered heterocycle is optionally substituted with up to two R^7 ;

each occurrence of R^7 is H, halogen, oxo, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₃-C₆ cycloalkyl,
 5 wherein said C₁-C₆ alkyl and said C₃-C₆ cycloalkyl can be optionally substituted with from one to four substituents which are independently selected from the group consisting of halogen, -OCH₃, -OH, -NH₂, -NHCH₃, and -N(CH₃)₂;

E is a 6-membered aryl or a 5- or 6-membered heteroaryl containing from one to three
 10 heteroatoms independently selected from the group consisting of S, O, and N, wherein said aryl and said heteroaryl are optionally substituted with up to four substituents, which are independently selected from the group consisting of halogen, -CN, -CF₃, -CHF₂, -CH₂NH₂, -CH₂NHCOCH₃, -OCF₃, -OCHF₂, -OH, -O-(C₁-C₆)alkyl, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

15 A is a heterocycle optionally substituted with up to four R^8 , or an aryl optionally substituted with up to four R^8 ;

each occurrence of R^8 is independently selected from the group consisting of halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkylheterocycloalkyl, heterocycloalkyl, -O-heterocycloalkyl,
 20 benzyl, -OCF₃, -OCHF₂, -OR³, =O, -CN, -NO₂, -SR³, -SF₅, -SCF₃, -SOR³, -SO₂R³, -S(=O)(=N)R², -N(R²)₂, -NR²COR³, -SO₂N(R²)₂, -NR²SO₂R³, -COOH, -COR⁹, -COOR³, -CON(R²)₂, =N(R²) and -C(R⁹)₂N(R²)₂, wherein said C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkylheterocycloalkyl, heterocycloalkyl, -O-heterocycloalkyl, and benzyl are optionally substituted with up to four methyl, F, -OCH₃, -OH, =O, NH₂, NHCH₃, or N(CH₃)₂; and

25 each occurrence of R^9 is independently selected from the group consisting of H, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 30 wherein R^1 is -CH₂NR²COR³, -CH₂OR⁴, -CH₂NR²SO₂R³, CH₂NR²COOR³, -CH₂OC(O)N(R²)₂, -CH₂N(R²)₂ or -CH₂R⁶;


R^2 is H;

R^3 is methyl, ethyl, bicyclo[1.1.1]pentane or cyclopropyl, wherein the cyclopropyl is

unsubstituted or substituted with methyl;

R⁴ is H; and

R⁶ is



5


3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is -CH₂NR²COR³, -CH₂OR⁴, CH₂NR²COOR³, or -CH₂R⁶;

R² is H;

R³ is methyl or cyclopropyl;

10 R⁴ is H; and



R⁶ is



4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein E is phenyl, substituted with one or two fluorine substituents.


15

5. The compound of any one of 1-4, or a pharmaceutically acceptable salt thereof, wherein A is:




20

wherein R⁸ represents up to four optional ring carbon substituents, wherein each occurrence of R⁸ is independently selected from the group consisting of fluorine, methyl, CN, SO₂CH₃,



5 6. The compound of any one of 1-4, or a pharmaceutically acceptable salt thereof, wherein A is:




wherein R⁸ represents up to four optional ring carbon substituents, wherein each occurrence of R⁸ is independently selected from the group consisting of H, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkylheterocycloalkyl, heterocycloalkyl, -O-heterocycloalkyl, benzyl, -OCF₃, -OCHF₂, -OR³, =O, -CN, -NO₂, -SR³, -SF₅, -SCF₃, -SOR³, -SO₂R³, -S(=O)(=N)R², -N(R²)₂, -NR²COR³, -SO₂N(R²)₂, -NR²SO₂R³, -COOH, -COR⁹, -COOR³, -CON(R²)₂, and -C(R⁹)₂N(R²)₂, wherein said C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkylheterocycloalkyl, heterocycloalkyl, -O-heterocycloalkyl, and benzyl are optionally substituted with up to four methyl, F, -OCH₃, -OH, =O, NH₂, NHCH₃, and N(CH₃)₂;

each occurrence of R² is independently selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₃-C₆ cycloalkyl, wherein said C₁-C₆ alkyl, said C₂-C₆ alkenyl, and said C₃-C₆ cycloalkyl can be optionally substituted with up to four substituents, which are independently
20 selected from the group consisting of halogen, -OCH₃, -OH, -NH₂, -NHCH₃, and -N(CH₃)₂;

R³ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, 4- or 5-membered heterocycloalkyl and C₃-C₆ cycloalkyl, wherein said C₁-C₆ alkyl, said C₂-C₆ alkenyl, 4- or 5-membered heterocycloalkyl and said C₃-C₆ cycloalkyl can be optionally substituted with up to four substituents, which are independently selected from the group consisting of halogen, C₁-C₆ alkyl, haloC₁-C₆ alkyl, CN, -OCH₃, -OH, -NH₂, -NHCH₃, and -N(CH₃)₂; and

each occurrence of R⁹ is independently selected from the group consisting of H, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl.

5 7. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein A is




wherein R⁸ represents up to four optional ring carbon substituents, wherein each occurrence of R⁸ is independently selected from the group consisting of halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkylheterocycloalkyl, heterocycloalkyl, -Oheterocycloalkyl, benzyl, -OCF₃, -OCHF₂, -OR³, =O, -CN, -NO₂, -SR³, -SF₅, -SCF₃, -SOR³, -SO₂R³, -S(=O)(=N)R², -N(R²)₂, -NR²COR³, -SO₂N(R²)₂, -NR²SO₂R³, -COOH, -COR⁹, -COOR³, -CON(R²)₂, and -C(R⁹)₂N(R²)₂, wherein said C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkylheterocycloalkyl, heterocycloalkyl, -Oheterocycloalkyl, and benzyl are optionally substituted with up to four methyl, F, -OCH₃, -OH, =O, NH₂, NHCH₃, and N(CH₃)₂;

each occurrence of R² is independently selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₃-C₆ cycloalkyl, wherein said C₁-C₆ alkyl, said C₂-C₆ alkenyl, and said C₃-C₆ cycloalkyl can be optionally substituted with up to four substituents, which are independently
20 selected from the group consisting of halogen, -OCH₃, -OH, -NH₂, -NHCH₃, and -N(CH₃)₂;

R³ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, a 4- or 5-membered heterocycloalkyl or C₃-C₆ cycloalkyl, wherein said C₁-C₆ alkyl, said C₂-C₆ alkenyl, said 4- or 5-membered heterocycloalkyl and said C₃-C₆ cycloalkyl can be optionally substituted with up to four substituents, which are independently selected from the group consisting of halogen, C₁-C₆ alkyl, haloC₁-C₆ alkyl, CN, -OCH₃, -OH, -NH₂, -NHCH₃, and -N(CH₃)₂; and

each occurrence of R⁹ is independently selected from the group consisting of H, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl.

8. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein A is:



wherein

each occurrence of R^8 is independently selected from the group consisting of H, halogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkylheterocycloalkyl, heterocycloalkyl, benzyl, $-OCF_3$, $-OCHF_2$, $-OR^3$, $=O$, $-CN$, $-NO_2$, $-SR^3$, $-SF_5$, $-SCF_3$, $-SOR^3$, $-SO_2R^3$, $-S(=O)(=N)R^2$, $-N(R^2)_2$, $-NR^2COR^3$, $-SO_2N(R^2)_2$, $-NR^2SO_2R^3$, $-COOH$, $-COR^9$, $-COOR^3$, $-CON(R^2)_2$, and $-C(R^9)_2N(R^2)_2$, wherein said C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkylheterocycloalkyl, heterocycloalkyl, and benzyl are optionally substituted with up to four methyl, F, $-OCH_3$, $-OH$, $=O$, NH_2 , $NHCH_3$, and $N(CH_3)_2$;

R^{10} is selected from the group consisting of H, C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl, wherein said C_1 - C_6 alkyl and said C_3 - C_6 cycloalkyl are optionally substituted with from one to four substituents, which are independently selected from the group consisting of F, $-OCH_3$, $-OH$, NH_2 , $NHCH_3$, and $N(CH_3)_2$;

R^{11} is selected from the group consisting of H, C₁-C₆ alkyl and C₃-C₆ cycloalkyl, $-\text{COR}^9$, $-\text{COOR}^9$, $-\text{CON}(\text{R}^9)_2$, and $-\text{SO}_2\text{R}^9$;

each occurrence of R^{12} is independently selected from the group consisting of H, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, benzyl, $-\text{OCF}_3$, $-\text{OCHF}_2$, $-\text{OR}^3$, $-\text{CN}$, $-\text{NO}_2$, $-\text{SR}^3$, $-\text{SF}_5$, $-\text{SCF}_3$, $-\text{SOR}^3$, $-\text{SO}_2\text{R}^3$, $-\text{S}(=\text{O})(=\text{N})\text{R}^2$, $-\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{COR}^3$, $-\text{SO}_2\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{SO}_2\text{R}^3$, $-\text{COOH}$, $-\text{COR}^9$, $-\text{COOR}^3$, $-\text{CON}(\text{R}^2)_2$, 4-membered heterocycle and $-\text{C}(\text{R}^9)_2\text{N}(\text{R}^2)_2$, wherein said C₁-C₆ alkyl, C₃-C₆ cycloalkyl, 4-membered heterocycle and benzyl are optionally substituted with up to four methyl, F, $-\text{OCH}_3$, $-\text{OH}$, NH_2 , NHCH_3 , and $\text{N}(\text{CH}_3)_2$;

10

R^{13} is selected from the group consisting of H, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, benzyl, $-\text{OCF}_3$, $-\text{OCHF}_2$, $-\text{OR}^3$, $-\text{CN}$, $-\text{NO}_2$, $-\text{SR}^3$, $-\text{SF}_5$, $-\text{SCF}_3$, $-\text{SOR}^3$, $-\text{SO}_2\text{R}^3$, $-\text{S}(=\text{O})(=\text{N})\text{R}^2$, $-\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{COR}^3$, $-\text{SO}_2\text{N}(\text{R}^2)_2$, $-\text{NR}^2\text{SO}_2\text{R}^3$, $-\text{COOH}$, $-\text{COR}^9$, $-\text{COOR}^3$, $-\text{CON}(\text{R}^2)_2$, and $-\text{C}(\text{R}^9)_2\text{N}(\text{R}^2)_2$, wherein said C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and benzyl are optionally substituted with up to four methyl, F, $-\text{OCH}_3$, $-\text{OH}$, NH_2 , NHCH_3 , and $\text{N}(\text{CH}_3)_2$; and


15

W is selected from the group consisting of O, S, SO, SO_2 , and $\text{S}(=\text{O})(=\text{NH})$; and


and wherein --- represents a double or a single bond.

20

9. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^8 is $-\text{SO}_2\text{R}^3$ and R^3 is independently selected from the group consisting of H, CH_3 , cyclopropyl and




25

wherein said  can be optionally substituted with up to two substituents, which are independently selected from the group consisting of methyl, ethyl, CN, fluoromethyl and fluorine.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the formula:

30




wherein, R^1 is $-\text{CH}_2\text{NR}^2\text{COR}^3$, $-\text{CH}_2\text{OR}^4$, $-\text{CH}_2\text{NR}^2\text{SO}_2\text{R}^3$, $\text{CH}_2\text{NR}^2\text{COOR}^3$, $-\text{CH}_2\text{OC}(\text{O})\text{N}(\text{R}^2)_2$, $\text{CH}_2\text{N}(\text{R}^2)_2$, or $-\text{CH}_2\text{R}^6$;

R^2 is H;

- 5 R^3 is methyl, ethyl, bicyclo[1.1.1]pentane or cyclopropyl, wherein the cyclopropyl is substituted with methyl;

R^4 is H; and

R^6 is:




10

11. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R^1 is $-\text{CH}_2\text{NR}^2\text{COR}^3$, wherein

R^2 is H; and


- 15 R^3 is methyl, ethyl, bicyclo[1.1.1]pentane or cyclopropyl, wherein the cyclopropyl is substituted with methyl.

12. The compound of any one of claims 1-4, or a pharmaceutically acceptable




20


13. The compound of claim 10, or a pharmaceutically acceptable salt thereof,



14. A compound, or a pharmaceutically acceptable salt thereof, having the structure:





15. The compound of claim 12, or a pharmaceutically acceptable salt thereof, having the structure:














16. A compound, or a pharmaceutically acceptable salt thereof, having the













structure:







	
	
	
	
	





17. The compound of claim 9, or a pharmaceutically acceptable salt thereof, having the structure:



5

18. A pharmaceutical composition which comprises a therapeutically effective amount of a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A method for treating a bacterial infection which comprises administering to a subject in need of such treatment (i) a therapeutically effective amount of a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or (ii) a pharmaceutical composition according to claim 16.

20. The method of claim 17, wherein the bacterial infection is due to *Mycobacterium tuberculosis*.

21. The method according to claim 17 or 18, wherein the compound or the pharmaceutically acceptable salt thereof is administered orally, parentally, or topically.

22. The method according to claim 17 or 18, wherein the *M. tuberculosis* is a drug resistant mycobacterial strain.

23. The method according to any one of claims 17-20, further comprising the step of administering a second therapeutic agent for treating *M. tuberculosis*.

24. The method of claim 21, wherein the second therapeutic agent is selected from the group consisting of: ethambutol, pyrazinamide, isoniazid, levofloxacin, moxifloxacin, gatifloxacin, ofloxacin, kanamycin, amikacin, capreomycin, streptomycin, ethionamide, prothionamide, cycloserine, terididone, para-aminosalicylic acid, clofazimine, clarithromycin, amoxicillin-clavulanate, thiacetazone, meropenem-clavulanate, and thioridazine.

25. Use of a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection in a subject, or in the manufacture of a medicament for treating a bacterial infection in a subject.